Hyperexcitability and epileptic seizures in a model of frontotemporal dementia

[1]  S. Younkin,et al.  Tau Loss Attenuates Neuronal Network Hyperexcitability in Mouse and Drosophila Genetic Models of Epilepsy , 2013, The Journal of Neuroscience.

[2]  H. Scharfman.  “Untangling” Alzheimer's Disease and Epilepsy , 2012, Epilepsy Currents.

[3]  R. Miledi,et al.  Loss of functional GABAA receptors in the Alzheimer diseased brain , 2012, Proceedings of the National Academy of Sciences.

[4]  F. Lee,et al.  Hyperdynamic Microtubules, Cognitive Deficits, and Pathology Are Improved in Tau Transgenic Mice with Low Doses of the Microtubule-Stabilizing Agent BMS-241027 , 2012, The Journal of Neuroscience.

[5]  G. Schellenberg,et al.  The genetics and neuropathology of Alzheimer’s disease , 2012, Acta Neuropathologica.

[6]  P. Szot.  Common factors among Alzheimer’s disease, Parkinson’s disease, and epilepsy: Possible role of the noradrenergic nervous system , 2012, Epilepsia.

[7]  Edward O. Mann,et al.  Inhibitory Interneuron Deficit Links Altered Network Activity and Cognitive Dysfunction in Alzheimer Model , 2012, Cell.

[8]  N. Corcoran,et al.  Targeting hyperphosphorylated tau with sodium selenate suppresses seizures in rodent models , 2012, Neurobiology of Disease.

[9]  B. Ghetti,et al.  Frontotemporal dementia: implications for understanding Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[10]  F. Hernández,et al.  Expression of frontotemporal dementia with parkinsonism associated to chromosome 17 tau induces specific degeneration of the ventral dentate gyrus and depressive-like behavior in mice , 2011, Neuroscience.

[11]  D. Small,et al.  Revisiting the Role of Acetylcholinesterase in Alzheimer’s Disease: Cross-Talk with P-tau and β-Amyloid , 2011, Front. Mol. Neurosci..

[12]  L. Mucke,et al.  Amyloid-β/Fyn–Induced Synaptic, Network, and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer's Disease , 2011, The Journal of Neuroscience.

[13]  B. Ghetti,et al.  Presence of Reactive Microglia and Neuroinflammatory Mediators in a Case of Frontotemporal Dementia with P301S Mutation , 2011, Neurodegenerative Diseases.

[14]  Jürgen Götz,et al.  Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models , 2010, Cell.

[15]  L. Mucke,et al.  Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks , 2010, Nature Neuroscience.

[16]  James B Leverenz,et al.  Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. , 2010, Brain : a journal of neurology.

[17]  Hyunmi Choi,et al.  Seizures in Alzheimer disease: who, when, and how common? , 2009, Archives of neurology.

[18]  R. Guerrero,et al.  Hyperphosphorylated tau aggregates in the cortex and hippocampus of transgenic mice with mutant human FTDP-17 Tau and lacking the PARK2 gene , 2009, Acta Neuropathologica.

[19]  H. Paudel,et al.  FTDP-17 missense mutations site-specifically inhibit as well as promote dephosphorylation of microtubule-associated protein tau by protein phosphatases of HEK-293 cell extract , 2009, Neurochemistry International.

[20]  L. Squire.  The Legacy of Patient H.M. for Neuroscience , 2009, Neuron.

[21]  Anatol C. Kreitzer,et al.  Aberrant Excitatory Neuronal Activity and Compensatory Remodeling of Inhibitory Hippocampal Circuits in Mouse Models of Alzheimer's Disease , 2007, Neuron.

[22]  V. Lee,et al.  BACE1 regulates voltage-gated sodium channels and neuronal activity , 2007, Nature Cell Biology.

[23]  L. Mucke,et al.  Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.

[24]  Bin Zhang,et al.  Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model , 2007, Neuron.

[25]  Florence Pasquier,et al.  Phenotype associated with APP duplication in five families. , 2006, Brain : a journal of neurology.

[26]  P. S. St George-Hyslop,et al.  Cortical neuronal and glial pathology in TgTauP301L transgenic mice: neuronal degeneration, memory disturbance, and phenotypic variation. , 2006, The American journal of pathology.

[27]  J. Lucas,et al.  Cooexpression of FTDP-17 tau and GSK-3β in transgenic mice induce tau polymerization and neurodegeneration , 2006, Neurobiology of Aging.

[28]  Massimo Mantegazza,et al.  Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy , 2006, Nature Neuroscience.

[29]  B. Ghetti,et al.  Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) , 2006, Orphanet journal of rare diseases.

[30]  A. Chakrabarti,et al.  Anti-seizure efficacy of nimodipine in pentylenetetrazole and kainic acid combined seizure models in mice. , 2006, Indian journal of physiology and pharmacology.

[31]  Yaakov Stern,et al.  Incidence and Predictors of Seizures in Patients with Alzheimer's Disease , 2006, Epilepsia.

[32]  M. Doran,et al.  Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin–1 gene , 2006, Journal of Neurology.

[33]  J. Ávila,et al.  Characterization of a double (amyloid precursor protein-tau) transgenic: Tau phosphorylation and aggregation , 2005, Neuroscience.

[34]  Jesus Avila,et al.  Role of tau protein in both physiological and pathological conditions. , 2004, Physiological reviews.

[35]  J. Lucas,et al.  FTDP-17 Mutations in tau Transgenic Mice Provoke Lysosomal Abnormalities and Tau Filaments in Forebrain , 2001, Molecular and Cellular Neuroscience.

[36]  O. Bugiani.  FTDP‐17: Phenotypical heterogeneity within P301S , 2000, Annals of neurology.

[37]  J. Ávila,et al.  The FTDP‐17‐Linked Mutation R406W Abolishes the Interaction of Phosphorylated Tau with Microtubules , 2000, Journal of neurochemistry.

[38]  N. Blom,et al.  Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. , 1999, Journal of molecular biology.

[39]  M G Spillantini,et al.  Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. , 1999, Journal of neuropathology and experimental neurology.

[40]  J. Ávila,et al.  Polymerization of tau peptides into fibrillar structures. The effect of FTDP‐17 mutations , 1999, FEBS letters.

[41]  Ronald C. Petersen,et al.  Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.

[42]  N L Foster,et al.  Frontotemporal dementia and parkinsonism linked to chromosome 17: A consensus conference , 1997, Annals of neurology.

[43]  D. Selkoe,et al.  Amyloid β-Protein and the Genetics of Alzheimer's Disease* , 1996, The Journal of Biological Chemistry.

[44]  M. Goedert,et al.  Monoclonal antibody PHF‐1 recognizes tau protein phosphorylated at serine residues 396 and 404 , 1994, Journal of neuroscience research.

[45]  M. Mendez,et al.  Seizures in Alzheimer's Disease: Clinicopathologic Study , 1994, Journal of geriatric psychiatry and neurology.

[46]  J. Morris,et al.  Advanced Alzheimer's disease is a risk factor for late-onset seizures. , 1990, Archives of neurology.

[47]  H. Wiśniewski,et al.  Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[48]  R. Racine,et al.  Modification of seizure activity by electrical stimulation. II. Motor seizure. , 1972, Electroencephalography and clinical neurophysiology.

[49]  Chang Zeng,et al.  Potential roles of Cdk5/p35 and tau protein in hippocampal mossy fiber sprouting in the PTZ kindling model. , 2010, Clinical laboratory.

[50]  I. Grundke‐Iqbal,et al.  Dysregulation of tau phosphorylation in mouse brain during excitotoxic damage. , 2009, Journal of Alzheimer's disease : JAD.

[51]  R. Guerrero,et al.  Park2-null/tau transgenic mice reveal a functional relationship between parkin and tau. , 2008, Journal of Alzheimer's disease : JAD.

[52]  M. Pallàs,et al.  Kainate induces AKT, ERK and cdk5/GSK3beta pathway deregulation, phosphorylates tau protein in mouse hippocampus. , 2007, Neurochemistry international.

[53]  M. Llorens-Martín,et al.  Pronounced individual variation in the response to the stimulatory action of exercise on immature hippocampal neurons , 2006, Hippocampus.

[54]  J. O'Callaghan,et al.  Enhanced expression of glial fibrillary acidic protein and the cupric silver degeneration reaction can be used as sensitive and early indicators of neurotoxicity. , 1992, Neurotoxicology.